openPR Logo
Press release

Allergic Conjunctivitis - Drug Pipeline Landscape, 2023 | Aldeyra Therapeutics, Allakos, Inmunotek, Regeneron Pharmaceuticals

02-14-2023 12:58 PM CET | Health & Medicine

Press release from: Global Insight Services

Allergic Conjunctivitis - Drug Pipeline

Allergic Conjunctivitis - Drug Pipeline

Allergic conjunctivitis is inflammation of the conjunctiva caused by an allergic reaction. Allergic conjunctivitis is caused by allergens and irritants, such as pollen, dust and mold. Allergic conjunctivitis can be grouped into two types seasonal allergic conjunctivitis and perennial allergic conjunctivitis.

To Remain 'Ahead' Of Your Competitors, Request for A Sample: https://www.globalinsightservices.com/request-sample/GIS31211

Symptoms of allergic conjunctivitis include red or pink eyes, pain, itchiness, swollen eyelids and soreness. Diagnostic tests of allergic conjunctivitis include an allergy skin test, a blood test and a scraping of conjunctival tissue may be taken to examine your white blood cells.

Drug treatment includes antihistamines, mast cell stabilizers, and occasionally, corticosteroids. Antihistamines may help bring fast relief from symptoms. The companies active in development of Allergic Conjunctivitis Drugs are Aldeyra Therapeutics, Inc., Inmunotek, Regeneron Pharmaceuticals, Vanda Pharmaceuticals, and Santen Pharmaceutical Co., Ltd.

Read more about Allergic Conjunctivitis - Drug Pipeline here: https://www.globalinsightservices.com/reports/allergic-conjunctivitis-drug-pipeline-landscape/

There are many clinical trials currently ongoing in Allergic Conjunctivitis Drug Development. Some of the most promising and well-designed trials are studying new medications and treatments for allergic conjunctivitis. These trials are testing the safety and effectiveness of these new medications and treatments, and they hold the potential to improve the quality of life for people with allergic conjunctivitis.

Report Highlights:

Global Insight Service's, Allergic Conjunctivitis - Drug Pipeline Landscape, 2023 report provides an overview of the Allergic conjunctivitis pipeline drugs. This report covers detailed insights on Allergic Conjunctivitis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Allergic Conjunctivitis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Get Customized Report as Per Your Requirement: https://www.globalinsightservices.com/request-customization/GIS31211

Methodology:

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope:

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Allergic Conjunctivitis treatment such as REGN1908-1909, Reproxalap, VSJ-110 and others. Key players involved in the development of therapies to treat Allergic Conjunctivitis are Aldeyra Therapeutics, Inc, Allakos, Inmunotek, Regeneron Pharmaceuticals, Vanda Pharmaceuticals and others. Five drugs are under late-stage Phase III clinical trials and one drug is in Phase II clinical trials and some other drugs are under Phase I clinical stages of development.

For In-Depth Competitive Analysis, Purchase this Report: https://www.globalinsightservices.com/checkout/single_user/GIS31211/

Contact Us:

Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Allergic Conjunctivitis - Drug Pipeline Landscape, 2023 | Aldeyra Therapeutics, Allakos, Inmunotek, Regeneron Pharmaceuticals here

News-ID: 2929458 • Views:

More Releases from Global Insight Services

Risk Management Software Market Is Anticipated To Expand From $14.9 Billion In 2024 To $32 Billion By 2034
Risk Management Software Market Is Anticipated To Expand From $14.9 Billion In 2 …
Market Overview The Risk Management Software Market is becoming an essential pillar for organizations across industries as they navigate an increasingly complex business environment. Companies face rising challenges ranging from regulatory compliance and cybersecurity threats to operational inefficiencies and supply chain disruptions. Risk management software provides a unified solution to identify, monitor, and mitigate these risks, enabling organizations to make informed decisions while safeguarding business continuity. These tools are not limited
Rare Disease Treatment Market Expected to Grow from $213.5 Billion in 2024 to $535.2 Billion by 2034 at 9.6% CAGR | Overall Study Report
Rare Disease Treatment Market Expected to Grow from $213.5 Billion in 2024 to $5 …
The Rare Disease Treatment Market is emerging as one of the most dynamic sectors in the global healthcare landscape. This market focuses on the development, production, and distribution of therapies designed to address rare and complex medical conditions affecting a small percentage of the population. Rare diseases, often genetic in origin, pose significant treatment challenges, which has prompted biopharmaceutical companies to invest in innovative solutions such as orphan drugs, gene
Digital Health Coaching Market Expected to Grow from $10.7 Billion in 2024 to $34.5 Billion by 2034 at 12.4% CAGR
Digital Health Coaching Market Expected to Grow from $10.7 Billion in 2024 to $3 …
The Digital Health Coaching Market is revolutionizing the healthcare and wellness landscape by offering personalized guidance through digital platforms. This market encompasses mobile applications, web-based platforms, and wearable devices that integrate artificial intelligence, data analytics, and behavioral science to provide tailored health programs. From chronic disease management to mental health support and nutrition coaching, digital health coaching empowers individuals to achieve their health goals conveniently and efficiently. The growing emphasis
Real-world Evidence (Rwe) Market Is Anticipated To Expand From $18.6 Billion In 2024 To $68.7 Billion By 2034
Real-world Evidence (Rwe) Market Is Anticipated To Expand From $18.6 Billion In …
Market Overview The Real-World Evidence (RWE) Market is becoming a cornerstone of modern healthcare, revolutionizing the way data is used to inform treatment decisions, drug development, and regulatory approvals. Unlike traditional clinical trials, which are conducted under controlled conditions, real-world evidence captures insights from everyday healthcare settings such as electronic health records, insurance claims, patient registries, and wearable devices. This approach provides a more comprehensive picture of how therapies perform in

All 5 Releases


More Releases for Allergic

Prominent Allergic Rhinitis Market Trend for 2025: Advancements In Treating Nasa …
Which drivers are expected to have the greatest impact on the over the allergic rhinitis market's growth? Anticipated growth in the allergic rhinitis market is predicted to be driven by increasing levels of air pollution and the impact of climate change. The term air pollution denotes the existence of harmful substances in our planet's atmosphere, which can negatively impact human health, damage the environment, and reduce the air's quality. Climate change
Allergic Rhinitis: A Comprehensive Overview
Allergic rhinitis, commonly known as hay fever, is a condition where an individual's immune system overreacts to allergens in the air. These allergens, which may include pollen, dust, or pet dander, trigger inflammation inside the nose, leading to symptoms like sneezing, a runny nose, itchy eyes, and congestion. While often associated with the spring and fall seasons due to pollen levels, allergic rhinitis can affect individuals year-round, depending on the
Allergic Conjunctivitis Market Statistics, Growth | Forecast
The new report published by The Business Research Company, titled ""Allergy Conjunctivitis Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends. As per the report, the allergy conjunctivitis market size has grown strongly in recent years. It will grow from $2.4 billion in 2023
Anti-Allergic Drugs Market Overview 2030
Anti-allergic drugs represent a pivotal domain in healthcare, providing advanced solutions to alleviate symptoms triggered by allergens. With an ever-growing prevalence of allergies globally, the anti-allergic drugs market is witnessing a significant surge. Valued at USD 26,234 Million in 2021, the market is poised to skyrocket to USD 47,566 Million by 2030, showcasing a robust CAGR of 6.8%. In the United States alone, where allergies affect 40 to 50 million
Allergic Conjunctivitis Market - Clear Eyes, Allergy-Free: Allergic Conjunctivit …
Newark, New Castle, USA: The "Allergic Conjunctivitis Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Allergic Conjunctivitis Market: https://www.growthplusreports.com/report/allergic-conjunctivitis-market/7892 This latest report researches the industry structure, sales, revenue,
Allergic Conjunctivitis Market - Empowering Eyes, Enhancing Lives: Redefining Al …
Newark, New Castle, USA - new report, titled Allergic Conjunctivitis Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Allergic Conjunctivitis market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Allergic Conjunctivitis market. The report offers an overview of the market, which